What Is Cervical Cancer Screening?
Cervical cancer screening is a routine medical check using tests to find changes in the cells of the cervix before cancer develops and before there are symptoms, to catch cervical cancer early when it is highly treatable. It is the systematic testing of women without symptoms in order to identify those who carry a higher risk of cervical precancer or cancer, so that they can be assessed and, where necessary, treated before disease develops or progresses.
The Purpose of Screening
The life course approach to cervical cancer prevention and control includes primary, secondary and tertiary prevention.
- Primary prevention. HPV vaccination is an effective tool for primary prevention. Additionally, a comprehensive strategy promoting healthy behaviours through age-appropriate information, sexual and reproductive healthcare, safe sex practices, and avoiding tobacco use has to be promoted.
- Secondary prevention. This includes screening and treating pre-cancerous lesions. Cervical cancer is largely curable if detected early and treated adequately. Effective screening methods include cytology, visual inspection, and the more reproducible — though more expensive — HPV DNA testing.
- Tertiary prevention. This involves treatment of invasive cancer at any age. However, detection in late stages makes it difficult to treat, is costly, and has a poor prognosis.
All these factors make a strong and viable prevention and screening programme necessary.
Screening is not intended for symptomatic women presenting with abnormal bleeding or a visible cervical lesion — they have to be investigated and need diagnostic evaluation regardless of any screening result. Screening addresses the much larger group of women who feel entirely well and have no reason to seek care. Its purpose is to find the small proportion within that group who need attention.
Why Early Detection of Cervical Abnormalities Matters
The natural history of cervical cancer has been studied extensively, and nearly all cervical cancer is caused by persistent infection with oncogenic strains of Human Papilloma Virus. The disease has a long pre-invasive phase of 10–15 years, which makes it amenable to early detection by screening and treatment by relatively simpler modalities (WHO, 2014).
Most HPV infections clear on their own. In a minority, infection persists and drives progressive change in the cells of the transformation zone, the junction between the outer squamous epithelium and the columnar lining of the cervical canal. That progression from persistent infection through precancerous change to invasive cancer typically takes years.
That long interval is the window of opportunity for clinical intervention. If detected as a:
- Precancerous lesion, the condition is usually managed with a short outpatient procedure.
- Invasive cancer, it requires major treatment with substantially worse outcomes.
The difference in clinical outcomes underlines the importance of screening and early diagnosis.
The Role of Screening in Preventive Healthcare
Cervical cancer is one of the leading causes of women's death worldwide, and the 2nd most common cancer among women in India after breast cancer. Considering its public health significance, it has always been a priority for global and national cancer control programs.
All countries must reach and maintain an incidence rate of below 4 per 100,000 women for cervical cancer to cease to be a public health problem. India contributes to one fifth of the global burden — around 1.2 lakh cases and over 77 thousand deaths.
Cervical cancer screening is essential in preventive healthcare because it can detect cell changes before they ever turn into cancer, making early disease diagnosis possible and making the disease treatable. Cervical screening is an important preventive measure within routine women's health services, alongside HPV vaccination, contraceptive counselling and a general cervical examination. Vaccination and screening are complementary, not alternatives: vaccination reduces future infection, screening addresses women who are already exposed or who were vaccinated after exposure. Programmes that run one without the other leave a substantial gap for decades.
Why Is Cervical Cancer Screening Important?
Early Detection
Precancerous cervical change produces little or no symptoms. By the time symptoms like intermenstrual or postcoital bleeding, persistent discharge or pelvic pain develop, the disease is advanced. Screening is the only practical route to detection during the phase when intervention is simplest.
Prevention and Timely Management
Cervical cancer prevention is realistic in a way that is uncommon in oncology. Screening identifies precancerous lesions; treating those lesions prevents the cancer from ever developing. Countries that have sustained organised screening programmes over decades have recorded substantial reductions in cervical cancer incidence and mortality, which is why cervical cancer elimination is now an explicit global health target rather than an aspiration.
Regular Screening
A single test report reflects one point in time. HPV infection can be acquired at any age and persistence develops over years — protection comes from repeated screening at the recommended interval rather than from any one negative result. The symptoms of a woman and clinical judgement are more important: a negative screen in a symptomatic woman cannot be ignored — a woman who develops abnormal bleeding six months after a normal result needs evaluation, not reassurance based on the earlier test.
Screening Ages and Intervals Vary by Country, by Guideline Body and by the Method Used
Follow the protocol issued by the relevant national programme or professional body. Broadly, most current guidance places routine screening in the 21 to 65 or 30 to 65 age range, at intervals of roughly three to five years for women with normal results. There are different protocols after an abnormal finding and for immunocompromised women.
The Role of Healthcare Professionals
Screening quality depends on the providers. Pap smear technique, sample adequacy, correct identification of the transformation zone of the cervix, accurate labelling of the sample, timely fixation of the cervical smear, reliable result communication and appropriate referral are all operator dependent. A programme with excellent test technology and weak operational discipline underperforms a simpler programme that is executed consistently. Training, standardised single use collection devices and defined recall systems are what convert a screening test into a screening programme.
Common Cervical Cancer Screening Methods
No single method of cervical cancer screening is appropriate and applicable everywhere. The right choice depends on age, national guidelines, laboratory infrastructure, workforce availability and the realistic likelihood that a woman returns for a second visit. The main cervical cancer screening methods in current use are set out below.
Human Papillomavirus (HPV) Testing
HPV testing is presently the preferred primary tool for cervical cancer screening because it directly identifies high-risk viral strains that cause nearly all cervical cancers.
Major health organizations recommend for average-risk individuals: primary HPV testing (preferred), performed every 5 years starting at age 25 or 30, continuing through age 65.
High risk HPV testing detects the DNA of oncogenic HPV types in a cervical sample. It is more sensitive than cytology for identifying women at risk of significant precancerous change, and a negative result carries a longer period of reassurance, which is why HPV based primary screening supports longer intervals. It is less specific, since many detected infections are transient and will clear without intervention, so a positive result normally goes to triage rather than straight to colposcopy.
Self collected HPV sampling, where the woman collects her own vaginal sample, is now recognised as a valid option in several guidelines and can substantially improve participation among women who do not attend clinic based screening.
Pap Testing and Cytology
Pap smear detects abnormal or precancerous cell changes. In Pap smear screening, cervical cells are examined under a microscope for morphological abnormality. It can be performed as conventional cytology, in which the sample is spread directly onto a slide and fixed, or as liquid based cytology, in which the collection device is transferred into a preservative vial. Cytology is more specific than HPV testing and describes the actual cell changes present, which is useful for triage decisions. It is less sensitive on a single test, which is why cytology only programmes rely on repetition at shorter intervals. Pap test alone as a screening test is performed every 3 years if primary HPV testing options are unavailable.
For the collection procedure in detail, see the Pap Smear Examination page.
Co-testing
Co-testing performs HPV testing and cytology on the same visit. It combines the sensitivity of HPV testing with the specificity of cytology and, where guidelines permit it, supports extended screening intervals for women who are negative on both. It also costs more per screen and requires both laboratory capabilities, so it is used mainly in settings with established cytology infrastructure. An HPV test combined with a Pap test is performed every 5 years.
Visual Inspection with Acetic Acid (VIA)
VIA is a low-cost, real-time cervical cancer screening method primarily utilized in low- and middle-income countries. It involves applying a 3% to 5% dilute acetic acid solution (household vinegar) to the cervix, and a trained healthcare provider examines it directly for acetowhite change. It requires no laboratory, gives an immediate result and can support a screen and treat approach in a single visit, which matters where a second visit is unlikely. It is operator dependent and less accurate than laboratory based methods. It is unsuitable for postmenopausal women in whom the transformation zone has receded into the canal. Several national programmes, including India's, have built population screening around it.
Follow-up Diagnostic Procedures
Screening for cervical cancer needs to be followed by further management. Where a screening result indicates risk, evaluation may involve colposcopy, directed biopsy of any abnormal area, and endocervical assessment where the lesion extends into the canal. Histopathology on that tissue is diagnostic, and not the screening test.
No method is universally appropriate. Method selection, age of entry and interval are set by national guidelines and local capability, and this page should be read alongside the applicable protocol rather than in place of it.
What Happens During Cervical Screening?
The cervical screening procedure is short. Most women are on the examination table for less than ten minutes.
Step 1: Patient Assessment
Involves consent, relevant history, last menstrual period, previous screening results, pregnancy and contraceptive status. Screening is done at an appropriate time, since heavy menstrual bleeding, recent intercourse, douching and intravaginal preparations can affect sample quality.
Step 2: Positioning
The woman is placed in the dorsal lithotomy position, appropriately draped, with attention to privacy and comfort.
Step 3: Speculum Examination
A vaginal speculum is inserted to hold the vaginal walls apart and expose the cervix.
Step 4: Cervical Visualisation
With adequate lighting, the clinician examines the whole cervix and identifies the external os and transformation zone. A visibly abnormal cervix requires referral for evaluation whatever the screening result later says.
Step 5: Sample Collection
Cells are collected from the ectocervix and the endocervical canal. A self-collected vaginal sample is used where HPV testing is done for screening. For VIA, acetic acid is applied and the cervix inspected directly instead.
Step 6: Laboratory Testing
The labelled sample travels with its requisition form for HPV assay, cytology, or both.
Step 7: Follow-up If Required
Results are communicated, and women with results indicating risk are recalled for triage or referred for colposcopy according to protocol.
The step by step collection technique, including device rotation, sample adequacy and fixation, is covered on the Pap Smear Examination page.
Medical Devices Used During Cervical Screening
Cyto Kit
The SMB Cyto Brush Kit is used for the collection of vaginal smear and Pap smear samples. It is intended for gynaecological sample taking only and is single use only.
Composition. Each gamma sterilised pouch contains one wooden Ayres spatula and one Gynobrush. Gamma sterilisation and single use packaging address cross contamination directly.
Role in sample collection.
- The Ayres spatula is designed specifically for obtaining Pap smears. Its concave end curves inward to fit against the cervix and is rotated in a circular fashion so that the entire area around the cervical os is sampled; the opposite end is used for scraping vaginal lesions or sampling the vaginal pool.
- The Gynobrush is designed for obtaining an endocervical smear by gently inserting the brush into the endocervical canal. Together they cover both the ectocervical surface and the canal, which is what allows a laboratory to judge a sample adequate.
Why Standardised Collection Matters at Programme Scale
When every collection across a facility or a screening round uses the same two devices in the same standardised way, accuracy rates become comparable between operators and between sites.
- Minimizes errors: Standard procedures ensure enough cells are collected from the transformation zone, reducing the rate of false negatives or inadequate samples.
- Consistency across providers: It ensures that the quality of the sample remains uniformly high.
- Accurate lab interpretation: Laboratories receive uniform specimens, making it significantly easier to accurately detect abnormal or precancerous cells.
- Programme efficiency: In large public health programs, it streamlines training, lowers overall costs by reducing the need for repeat testing, and allows for reliable data tracking to measure the programme's success.
Vaginal Speculum
A speculum is required to expose the cervix in every clinician collected method, including VIA. SMB manufactures a transparent, duckbill shaped single use speculum made from clear, high strength, non-toxic polymer, available in medium and small, with a locking function that holds the vaginal walls securely and allows self retention in a range of positions. Single use specula remove reprocessing time and cost and reduce the cross contamination risk associated with incomplete cleaning or sterilisation of metal instruments.
View Speculum ↗Cervical Dilator
Cervical dilation is not part of routine cervical screening. A screening sample is taken from the cervical surface and the outer canal, and nothing needs to pass the internal os.
Dilation is relevant only in selected clinical situations, principally cervical stenosis. That is a clinical judgement made by the treating physician.
The SMB Cervical Dilator, also known as the Progressive Dilator, is a single use, gamma sterilised device with a rounded tip intended to facilitate cervical dilation for endo-uterine examination. Its distal portion has four to five segments depending on the model, small or large, each measuring 1.5 cm, with progressively increasing diameter from the distal end. The rounded tip is designed to prevent puncture of the uterine wall. It is intended for use by, or under the supervision of, a qualified healthcare professional, and carries defined contraindications, warnings and precautions in its instructions for use.
View Cervical Dilator ↗Pozzi Tenaculum Forceps
A tenaculum is not required for routine cervical screening. Collecting a cervical sample does not normally call for cervical traction or stabilisation.
The instrument is used in certain diagnostic and gynaecological procedures where the cervix must be steadied or the uterocervical angle reduced so that an instrument can pass the canal — for example during IUD insertion — or where a clinician needs stable traction during a procedure on the cervix or uterine cavity.
The SMB Pozzi Tenaculum Forceps, also known as cervix holding forceps, is a single use device made from medical grade polycarbonate. Its jaws end in sharp inward pointing hooks for precise tissue grasping and to optimise traction of the cervix; the thinner end is designed to give the practitioner better visibility, and the ratchet locking mechanism holds the grip. Its stated intended use is to hold the cervix during IUD insertion. The device should be used by, or under the supervision of, a physician or gynaecologist.
View Pozzi Tenaculum Forceps ↗Screening vs Diagnostic Evaluation
These two things are routinely confused by patients and occasionally blurred in clinical communication, which produces both unnecessary alarm and false reassurance.
| Screening | Diagnostic Evaluation | |
|---|---|---|
| Applies to | Women without symptoms | A woman with an abnormal screening result, symptoms, or a clinically suspicious cervix |
| Question it answers | Who needs a closer look? | What is actually present? |
| Typical tests | HPV testing, cytology, co-testing, VIA | Colposcopy, directed biopsy, endocervical assessment, histopathology |
| What the result gives you | A level of risk | A diagnosis |
| Acts on it | Programme protocol, recall and referral | Clinical management decision |
Screening identifies people who may need further evaluation. A positive or abnormal screen is a signal to look closer, not a finding of disease.
Diagnostic evaluation investigates an abnormal finding or a clinical concern. Colposcopy allows magnified examination of the cervix and biopsy of any suspicious area, and it is the histopathology on that tissue that determines what, if anything, is treated.
The practical consequence: an abnormal screening result should be communicated as a reason for a further test, and a symptomatic woman should proceed to diagnostic evaluation even if her last screen was normal.
Related reading: Colposcopy Procedure
Importance of Follow-Up
An Abnormal Screening Result Does Not Mean Cancer
Most abnormal cervical screening results do not indicate cancer. A positive HPV test most often reflects an infection that will clear. Low grade cytological change frequently regresses without intervention. The result places a woman in a group that warrants a further look, and how that message is delivered materially affects whether she comes back for it.
Follow-up Depends on the Result and Clinical Assessment
The next step is determined by the type of cervical cancer screening method used, the screening result, the woman's age, her HPV status where known, her medical, obstetric and clinical history, and the applicable national protocol. Depending on those factors it may be repeat testing at a defined interval, HPV triage of an abnormal cytology result, cytology triage of a positive HPV result, or direct referral for colposcopy.
Additional Testing May Be Recommended
Where colposcopy is indicated, directed biopsy and, if the lesion extends into the canal, endocervical assessment may follow. Treatment decisions rest on the histopathology result.
Where Programmes Actually Fail
Loss to follow up is consistently a larger source of programme failure than collection technique. A facility can achieve excellent sample adequacy and still deliver almost no clinical benefit if women with abnormal results are not contacted, not referred, or not seen. A functioning programme needs a defined recall mechanism, a named person accountable for communicating results, a documented referral route and a way to detect who has fallen out of the pathway.
About This Page
This page is intended as general clinical and product reference information for healthcare professionals and institutional buyers. It is not medical advice and does not replace the clinical judgement of a qualified practitioner or the instructions for use supplied with any device.
FAQs
What is cervical cancer screening?
Cervical cancer screening is the testing of women without symptoms to identify those at higher risk of cervical precancer or cancer. It uses HPV testing, cytology (Pap smear), co-testing or visual inspection, depending on the national programme. Screening indicates who needs further evaluation; it does not by itself diagnose cancer.
Who should undergo cervical screening?
Screening ages and intervals differ by country, by guideline body and by method. Most current guidance covers women from age 21 or 30 up to around 65, at three to five year intervals when results are normal, with different protocols after an abnormal result and for immunocompromised women. Follow the applicable national protocol.
What is the difference between Pap testing and HPV testing?
HPV testing detects high risk human papillomavirus, the cause of nearly all cervical cancer, and is more sensitive for identifying risk. Pap testing examines cervical cells for abnormal changes and is more specific about what is actually present. Many programmes use HPV as the primary test with cytology for triage, or perform both together.
How is a cervical sample collected?
A speculum is inserted to expose the cervix. Cells are collected from the ectocervical surface with a spatula and from the endocervical canal with a brush, then placed on a slide or into a liquid based cytology vial. Some HPV programmes allow the woman to collect a vaginal sample herself.
What happens after an abnormal screening result?
An abnormal result means further assessment is needed, not that cancer is present. Depending on the result, age and protocol, the next step may be repeat testing, HPV or cytology triage, or referral for colposcopy with directed biopsy. Any treatment decision is based on the biopsy result, not the screening test.
What instruments are used during cervical screening?
A vaginal speculum to expose the cervix, and a spatula plus endocervical brush to collect the cervical sample, with a slide and fixative or a liquid based cytology vial. A cervical dilator or a tenaculum is not part of routine screening and is used only in selected clinical situations where cervical access or stabilisation is required.
Looking for Reliable Cervical Screening Devices and Instruments?
Contact SMB Corporation of India for product information, OEM solutions, and global supply support.
